Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

4.31USD
2:46pm EDT
Change (% chg)

$0.05 (+1.17%)
Prev Close
$4.26
Open
$4.10
Day's High
$4.40
Day's Low
$3.95
Volume
43,466
Avg. Vol
45,559
52-wk High
$12.76
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Merrimack Reports Q2 Loss Per Share $1.33
Tuesday, 7 Aug 2018 06:30am EDT 

Aug 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.33.Q2 EARNINGS PER SHARE VIEW $-1.28 -- THOMSON REUTERS I/B/E/S.MERRIMACK - BELIEVES CURRENT RESOURCES SUFFICIENT TO FUND PLANNED OPERATIONS INTO AT LEAST Q1 2020.  Full Article

Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33
Tuesday, 8 May 2018 06:25am EDT 

May 8 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 OPERATING LOSS PER SHARE $1.33.THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES.MERRIMACK - BELIEVE CASH,CASH EQUIVALENTS OF $76.3 MILLION AS OF MARCH 31&SOME MILESTONE PAYMENTS ANTICIPATED FROM SHIRE TO BE ENOUGH TO FUND INTO H2 2019.  Full Article

Merrimack Provides Business Update And Reports 2017 Financial Results
Monday, 12 Mar 2018 06:27am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS.‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​.‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​.MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​.MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019.Q4 LOSS PER SHARE $0.89.  Full Article

Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
Monday, 12 Mar 2018 06:25am EDT 

March 12 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER.MERRIMACK PHARMACEUTICALS INC - ‍RANDOMIZED PHASE 2 STUDY ACCRUAL RAISED TO 100 PATIENTS; DATA STILL EXPECTED LATER THIS YEAR​.MERRIMACK PHARMACEUTICALS INC - ‍MERRIMACK CONTINUES TO ANTICIPATE TOP-LINE DATA FROM SHERLOC STUDY IN SECOND HALF OF 2018​.  Full Article

Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 04:40pm EST 

Dec 15 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Merrimack reports Q3 loss per share from continuing operations $0.40
Wednesday, 8 Nov 2017 06:40am EST 

Nov 8 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack reports third quarter 2017 financial results.Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40.Merrimack Pharmaceuticals-Believes unrestricted cash & cash equivalents & payments from shire will be sufficient to fund operations into H2 2019.  Full Article

Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
Monday, 30 Oct 2017 06:55am EDT 

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer.Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​.Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​.  Full Article

Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes
Friday, 13 Oct 2017 07:30am EDT 

Oct 13 (Reuters) - Merrimack Pharmaceuticals Inc ::Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020.Merrimack Pharmaceuticals-commenced tender offer to buy $25.03 million aggregate principal amount of outstanding 4.50 pct convertible senior notes due 2020​.  Full Article

Merrimack announces settlement of convertible note litigation
Tuesday, 10 Oct 2017 04:24pm EDT 

Oct 10 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack announces settlement of convertible note litigation.Merrimack Pharmaceuticals Inc - ‍agreement resolves outstanding litigation associated with Merrimack's asset sale to Ipsen​.Merrimack - ‍agrees to commence tender offer to purchase outstanding convertible notes with potential to eliminate all remaining debt​.Merrimack Pharmaceuticals Inc - Merrimack does not intend to declare an additional special dividend with any funds from escrow​.Merrimack-Under terms of settlement,co to pay noteholder plaintiffs $0.90 per $1.00 of convertible notes,plus accrued interest,an amount for legal fees​.Merrimack Pharmaceuticals -tender offer to acquire all remaining convertible notes at rate $0.90 per $1.00 of convertible notes, plus accrued interest​.Merrimack -‍settlement payout,amount co expects to pay for remaining notes,expenses related to Delaware action to be about $60 million released from escrow​.  Full Article

Merrimack announces date of one-for-ten reverse stock split
Thursday, 31 Aug 2017 08:00am EDT 

Aug 31 (Reuters) - Merrimack Pharmaceuticals Inc :Merrimack announces date of one-for-ten reverse stock split.Merrimack Pharmaceuticals Inc says ‍one-for-ten reverse stock split- shares of common stock will begin trading on split-adjusted basis on September 6​.  Full Article

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.